title: Immunohistochemical activity of Prohibitin-2 and Stomatin-Like Protein-2 in patients with ulcerative colitis.
abstract: OBJECTIVE
  We aimed to semi-quantitatively investigate prohibitin-2 (Phb-2) and stomatin-like protein-2 (Slp-2) expressions in patients with ulcerative colitis (UC) and healthy controls using the immunohistochemical (IHC) method. We also aimed to evaluate the correlations between the activity of UC and the expressions of these two proteins.
  
  
  METHODS
  Ninety-five patients with UC (82 males and 13 females) and 38 healthy controls (35 males and 3 females) were included. Clinical and endoscopic activities of UC were assessed. Conventional laboratory activation parameters and severity of inflammation measures were used for the evaluation of histological activity. IHC staining of biopsy samples for the two proteins were semi-quantitatively applied, similar to previously described methods for colon adenocarcinomas.
  
  
  RESULTS
  IHC scores of Phb-2 were lower but Slp-2 scores were higher in the UC group than in the healthy controls (p<0.05 and p=0.003, respectively). Phb-2 scores were positively correlated with clinical and histological activities (r=0.364, p<0.05 and r=0.220, p<0.032, respectively). In the UC group, endoscopic activity scores, C-reactive protein levels, and sedimentation rates were also positively correlated with Phb-2 scores (r=0.279, p<0.05, r=0.216, p<0.05, and r=0.216, p<0.05, respectively). IHC scores of Slp-2 were not significantly correlated with the activity parameters of UC. However, there was a significant positive correlation between the expressions of Phb-2 and Slp-2 proteins (p<0.001).
  
  
  CONCLUSIONS
  Phb-2 may serve as a valuable new biomarker for predicting the severity of all UC activity parameters. The therapeutic effectiveness of both Phb-2 and Slp-2 should be taken into consideration.
authors.affiliation: Department of Gastroenterology, Gülhane Military Medical Academy Haydarpaşa Training and Research Hospital, İstanbul, Turkey. alpaslantanoglu@yahoo.com.
authors.forename: İrfan
authors.initials: İ
authors.lastname: Küçük
authors.forename: Alpaslan
authors.initials: A
authors.lastname: Tanoğlu
authors.forename: Kemal
authors.initials: K
authors.lastname: Öncü
authors.forename: İsmail
authors.initials: İ
authors.lastname: Yılmaz
authors.forename: Muammer
authors.initials: M
authors.lastname: Kara
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Beyazıt
authors.forename: Taner
authors.initials: T
authors.lastname: Akyol
authors.forename: Mustafa
authors.initials: M
authors.lastname: Kaplan
authors.forename: Halil Onur
authors.initials: HO
authors.lastname: Özarı
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yazgan
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000032:analysis; D001706:Biopsy; D001798:Blood Proteins / Q000378:metabolism*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D003093:Colitis, Ulcerative / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D003113:Colonoscopy / Q000379:methods; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D000091402:Prohibitins; D012097:Repressor Proteins / Q000378:metabolism*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; D008565:Membrane Proteins; C000717328:PHB protein, human; C000717331:PHB2 protein, human; D000091402:Prohibitins; D012097:Repressor Proteins; C406287:STOML2 protein, human; D002097:C-Reactive Protein